LSD at the End of Life: From Island to the Clinic

“Huxley died with LSD. The clinical program he helped create is now treating the same anxiety, cancer, dying, the dissolution of the self, that he faced in November 1963.”

On November 22, 1963, the day John F. Kennedy was assassinated, though neither Aldous Huxley nor his wife Laura knew this, Huxley was dying of laryngeal cancer. He had lost the ability to speak. He wrote a note asking Laura to administer LSD. She gave him LSD in the late morning and again in the early afternoon, speaking to him softly as he died: 'You are doing this willingly and consciously, and you are doing this beautifully.'

The nurses who were present said they had never seen such a peaceful death.

This event, which Laura Huxley described in a letter to Osmond written shortly after, published in This Timeless Moment, was not an improvisation. It was the culmination of a decade of thinking about what psychedelics could do at the end of life, a decade that began with the Huxley-Osmond correspondence and found its fullest fictional expression in Island (1962), where the moksha-medicine was explicitly integrated into the community's approach to dying.

Huxley had written about death as one of the three or four things that psychedelics could transform. Not prevent, not deny, transform. The moksha experience, in his account, was particularly relevant to dying because what dying required, a release of the ego's grip on its own continuity, an opening to whatever lay on the other side of the known, was precisely what the psychedelic experience trained. The person who had genuinely dissolved the ego's boundaries in a guided session had, in some sense, rehearsed dying.

Osmond, as a psychiatrist who worked regularly with seriously ill patients, had thought about this from the clinical side. He had observed that the LSD sessions with terminal patients produced responses unlike those in other populations: a quality of peace, acceptance, and even gratitude that was not explicable by any pharmacological action on disease symptoms. Whatever was happening was happening to the relationship between the person and their situation, not to the situation itself.

The clinical program that tested this systematically did not begin until after Huxley's death. Walter Pahnke's work at the Maryland Psychiatric Research Center in the 1960s and 1970s established that LSD-assisted therapy significantly reduced anxiety and depression in terminal cancer patients. The research was stopped by prohibition in 1970.

The program resumed, with psilocybin rather than LSD, in 2016, with two landmark studies published simultaneously. Griffiths et al. at Johns Hopkins and Ross et al. at NYU found, in separate double-blind trials, that a single session of psilocybin-assisted therapy produced rapid and sustained reductions in end-of-life anxiety and depression in cancer patients, with effects persisting at six-month follow-up. The mechanism, consistent across both studies, was mystical experience quality: patients who had complete mystical experiences showed the greatest therapeutic benefit.

Australia's Therapeutic Goods Administration approved psilocybin for treatment-resistant depression and MDMA for PTSD in February 2023, the first regulatory approvals for psychedelic-assisted therapy in any country outside of a trial setting. The approval includes provisions for palliative care contexts.

Huxley wrote Laura's words at the end of life into Island: 'Willingly and consciously and beautifully, you're doing it willingly and consciously and beautifully.' He wrote them into his novel two years before he died; Laura used them at his bedside because they were the right words, because he had worked out what the right words were in decades of thinking about how the mind met its own dissolution.

The clinical program that now provides this to dying patients in clinical trials is the institutionalized version of what Huxley worked out in his letters to Osmond. The language has changed, outcomes, endpoints, MADRS scores, but the underlying event, and the reason it helps, is what the correspondence described.

Sources

• Huxley & Osmond, in Moksha (1977)
• Griffiths et al., Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer, J Psychopharmacol (2016)
• Ross et al., Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer, J Psychopharmacol (2016)
• TGA Australia, Psilocybin clinical approval (February 2023)